Science raises $230 millions to challenge Neuralink as the commercialization race for brain-computer interfaces heats up

Golden Ten Data reported on March 5 that neurotechnology company Science Corp has raised $230 millions from investors to commercialize its implant device for the visually impaired and to develop more advanced brain devices. According to informed sources, after this round of financing, Science's valuation (including new funds) has reached $1.25 billions. This makes it the second highest-valued brain-computer interface company in the world, following Musk's startup Neuralink. At the same time, the company is also one of the best-funded, having raised a total of $489 millions to date. A study published last October in The New England Journal of Medicine showed that the system improved the vision of 26 out of 32 patients with late-stage age-related macular degeneration. In recent years, investors have poured more than $2 billions into the six major brain-computer interface companies in the United States. Currently, the U.S. Food and Drug Administration (FDA) has not approved any devices for long-term commercial use, so these devices are only available in clinical trials.